Connection

Nirav Shah to Leukemia, Lymphocytic, Chronic, B-Cell

This is a "connection" page, showing publications Nirav Shah has written about Leukemia, Lymphocytic, Chronic, B-Cell.
  1. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 09 26; 144(13):1374-1386.
    View in: PubMed
    Score: 0.210
  2. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jul 06; 389(1):33-44.
    View in: PubMed
    Score: 0.193
  3. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
    View in: PubMed
    Score: 0.192
  4. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901.
    View in: PubMed
    Score: 0.164
  5. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 11; 9(22):8468-8479.
    View in: PubMed
    Score: 0.159
  6. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989.
    View in: PubMed
    Score: 0.158
  7. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
    View in: PubMed
    Score: 0.144
  8. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 11; 93(11):1394-1401.
    View in: PubMed
    Score: 0.139
  9. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 09; 103(9):1511-1517.
    View in: PubMed
    Score: 0.136
  10. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.